Beyond protection: Turning patent portfolios into commercial advantage

​
November 12, 2026
Why the strongest patent strategies begin with business value - not patent volume

The proposition

A patent portfolio can be legally impressive and commercially disappointing. The real test is not how many patents a business owns, but what those patents enable it to do. For many organisations, patents are still viewed primarily as defensive legal tools. But in today’s innovation-driven economy, the strongest portfolios do much more: they support growth, investment, partnerships, valuation and competitive advantage.
Patents remain important defensive rights. They can deter copying, create barriers to entry and provide leverage when a competitor gets too close. But protection is only the starting point. A portfolio creates real value when it is connected deliberately to the company’s products, markets, funding strategy and commercial relationships. Without that connection, even technically strong patents can become an expensive record of past innovation.

1. A patent is not valuable merely because it has been granted

A grant certificate proves that a legal threshold has been met. It does not prove that the patent protects a product customers want, covers a commercially important market or would survive a determined validity challenge.

That distinction matters because patents are expensive throughout their life. Filing, prosecution, overseas protection, translations, renewals and enforcement all compete for capital. The objective should not be to accumulate rights, but to build a portfolio whose scope, ownership and geographic coverage support a credible commercial position.

Nor is quantity a reliable proxy for strength. Five well-chosen patent families may do more for a business than fifty peripheral filings. Value depends on what the claims cover, how difficult they are to design around, whether the rights align with the market and whether the business can use them in practice.

The strongest portfolios are built with the end goal in mind from the beginning.

2. Start with the commercial objective

In my experience, the most productive patent discussions begin not with “Can we patent this?” but with “What commercial position are we trying to create?”

That question changes the conversation. It requires the business to identify the products and services that matter, the markets it expects to enter, the competitors or partners it may encounter and the capabilities that genuinely differentiate it. Filing decisions can then be tested against those objectives rather than driven by technical novelty alone.

This is critical in deep tech: quantum, artificial intelligence, life sciences, semiconductors and advanced engineering, where technologies and business models can evolve faster than the patent process. The portfolio must move with the business - not anchor it to an obsolete roadmap.

3. Use patents to create options: investment, licensing and partnerships

The commercial power of a patent is often its ability to create options. For an investor or acquirer, a coherent portfolio can evidence ownership, technical differentiation and a disciplined approach to future growth. It can support valuation, although it does not determine valuation on its own.

Patents can also make collaboration easier. Clearly defined rights help parties understand what each is bringing to a joint development, what access is required and how resulting technology may be commercialised. That clarity can reduce friction in negotiations with larger industrial partners, research institutions and other members of an innovation ecosystem.

Licensing adds another route to value. A business need not manufacture every product or enter every territory itself. Rights that are peripheral to one company’s strategy may be central to another’s. But licensing revenue is not automatic: it depends on market demand, useful claim scope, credible ownership and a counterparty with a commercial reason to take a licence.

4. Review ruthlessly: quality, relevance and cost

A portfolio should not be treated as a museum. Products change, markets close, competitors move and once-promising technologies lose relevance. Regular review is therefore as important as initial filing.

Each patent family should earn its place. Does it still support a current or credible future product? Is the protected market important? Does the right constrain a competitor, strengthen a negotiation or offer a realistic licensing opportunity? Are the likely benefits proportionate to the next round of prosecution and renewal costs?

Where the answer is no, sale, licensing or abandonment may be the disciplined choice. Pruning is not a sign that the original filing failed. It is evidence that the portfolio is being managed as a business asset.

5. Protection is only one part of the IP strategy

A balanced and credible strategy also recognises what patents cannot do. Patent ownership does not establish freedom to operate: a business may own valuable rights and still risk infringing an earlier third-party patent. Nor is patenting always the best answer. Filing requires disclosure, enforcement can be costly and some innovations are better protected through confidentiality, accumulated know-how, contractual controls, data advantages or speed to market.

The right question is therefore not whether patents are inherently valuable. It is where they add value relative to the alternatives. For some technologies, a patent will be the foundation of market exclusivity. For others, it will be one element in a broader package of rights and practical barriers that competitors cannot easily reproduce.

6. Conclusion: make the portfolio work for the business

The strongest patent strategies are neither filing exercises nor defensive reflexes. They are commercial disciplines. They connect protection decisions to products, markets, capital, partnerships and competitive choices - and they change when the business changes.

That means filing selectively, documenting ownership, reviewing the portfolio honestly and being clear about the outcome each right is intended to support. It also means recognising when another form of protection would serve the business better.

The goal is not simply to own patents. The goal is to make the portfolio work for the business.

Turn your patent portfolio into a commercial asset

Looking to get more value from your patents? Talk to our team about developing a patent strategy aligned with your commercial ambitions.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Beyond protection: Turning patent portfolios into commercial advantage
12 November 2026
A strong patent portfolio should do more than protect innovation. It should support the wider commercial ambitions of the business. This article explores how businesses can move beyond simply accumulating patents and instead build portfolios that create genuine commercial value. From aligning filing decisions with products and markets to supporting investment, licensing and partnerships, it considers how a focused patent strategy can strengthen competitive advantage while ensuring every right continues to earn its place.
Samsung v ZTE: Will multiple rate setting trials become more common?
12 November 2026
The Samsung v ZTE dispute has highlighted the growing potential for multiple courts to determine FRAND rates within the same licensing dispute. This article explores how approaches in the UK, China and potentially the UPC could shape future FRAND litigation, the challenges posed by competing rate determinations, and whether arbitration could offer an alternative route to resolution.
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.